1
Discover top-quality products tailored for scientific and medical research. Request a personalized quote today
to enhance your projects.
| Product Code | Bt-474; BT474 |
| Species | Human |
| Cat.No | ABC-TC0085 |
| Product Category | Tumor Cell Lines |
| Size/Quantity | 1 vial |
| Cell Type | Epithelial |
| Shipping Info | Dry Ice |
| Growth Conditions | 37 ℃, 5% CO2 |
| Source Organ | Breast |
| Disease | Ductal Cancer |
| Biosafety Level | 1 |
| Storage | Liquid Nitrogen |
| Product Type | Human Breast Cancer Cell Lines |
The BT-474 cell line, originating from a 60-year-old White female breast cancer patient, showcases epithelial traits and emerges from an invasive ductal carcinoma of the breast. Notably, the BT-474 cells are identified as estrogen receptor positive (ER), progesterone receptor positive (PR),
and human epidermal growth factor receptor 2 positive (HER2). These cells form compact, slowly growing multi-layered colonies, rarely achieving confluence and failing to create a continuous monolayer. Impressively, they exhibit tumorigenic characteristics in athymic mice and demonstrate susceptibility to the mouse mammary tumor virus. Additionally, a mutation in the TP53 gene is identified within the BT-474 cell line.
Why choose BT-474 from AcceGen?
AcceGen’s BT-474 cell line features exceptional viability and quality, confirmed through rigorous quality control measures. The cells are maintained in a sterile environment and have been thoroughly tested to ensure they are free from bacterial, fungal, and mycoplasma contamination. Identity verification utilizing STR analysis further guarantees the authenticity and reliability of the BT-474 cell line.
When you publish your research, please cite our product as “AcceGen Biotech Cat.# XXX-0000”. In return, we’ll give you a $100 coupon. Simply click here and submit your paper’s PubMed ID (PMID).
FOR RESEARCH USE ONLY
The BT-474 cell line finds valuable applications in preclinical breast cancer research, offering a direct link to real patients with matching genetic profiles. This model proves indispensable in drug discovery endeavors, facilitating the development of innovative targeted treatments for breast cancer. Its utilization spans from investigating small molecules and antibodies to refining cell-based therapies, enhancing the prospects of advancing effective interventions for breast cancer patients.
